Technology Listings


Compounds for the Treatment of Influenza

Application

Pharmaceutical compositions containing glutathione and glutathione disulfide for the prevention and treatment of influenza.

Key Benefits
  • Glutathione and glutathione disulfide compositions can be applied directly to the epithelia.
  • Can be delivered through inexpensive and practical delivery methods, such as lozenges, oral rinses, and nasal sprays.
  • Acts without interfering with the body's natural elimination of infected cells.
  • May be effective on multiple influenza strains due to its method of action.
Technical Summary

The glutathione and glutathione disulfide compositions used in this technology inhibit the production of infectious virus particles likely by interrupting the protease cleavage of viral hemagglutinin after the viral particles are released. By preventing extracellular activation of the virus, these compositions do not interfere with intracellular processes, allowing apoptosis of infected cells to proceed normally. Because the compositions work extracellularly, they can be delivered directly without the use of injections. Finally, this technology, by acting directly on the virus rather than conferring immunity to specific strains, may act to prevent and treat a broader range of strains than traditional immunization techniques.

Developmental Stage

This technology has been observed to protect against virus production in human small airway endothelial cells.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Utility(parent) United States 09/005,747 6,013,632 1/12/1998 1/11/2000 1/12/2018
Nationalized PCT - Foreign EP 98902446.8 1007077 B1 1/12/1998 10/7/2009  
Nationalized PCT - Foreign Japan 10-531111 4578578 1/12/1998 9/5/2010 1/12/2018
Nationalized PCT - Foreign Canada 2,277,911 2,277,911 1/12/1998 9/14/2010  
EP Registered Country Italy 989024468.8 1007077 B1 1/12/1998 10/7/2009 1/12/2018
EP Registered Country Switzerland 989024468.8 1007077 B1 1/12/1998 10/7/2009 1/12/2018
EP Registered Country United Kingdom 989024468.8 1007077 B1 1/12/1998   1/12/2018
Nationalized PCT - Foreign Korea, Republic of 10-1998-0023595 585242 1/23/1998 5/24/2006  
Divisional United States 09/339,629 6,107,281 6/24/1999 8/22/2000 1/12/2017
Tech ID: 98020
Published: 3/23/2010
Category
Therapeutics

Contact
Cale Lennon
Director, Licensing
Emory University
404-712-4758
jlennon@emory.edu

Inventor(s)
Dean Jones
Satoru Furukawa

Keywords
Microbiology/Infectious Diseases
Biologic